The Latest Cardiac and Vascular News
Transformative XO Angioplasty Platform Expands with Low-Profile 2.2F and 3.8F Rapid-Exchange (RX) with the Ability to Treat Up to 20cm Lesions with (1) Inflation SALT LAKE CITY, Oct. 27, 2022 /PRNewswire/ — Transit Scientific, a pioneer in developing medical devices to treat calcified cardiovascular disease, dilate stenosed intimal hyperplasia, and access, cross, […]
This registry will confirm safety and performance of the VBX Stent Graft in peripheral vessels in patients who require interventional treatment in a variety of applications and diseases. PUTZBRUNN, Germany, Oct. 27, 2022 /PRNewswire/ — W. L. Gore & Associates, Inc. (Gore) announced the completion of target enrollment in the EXPAND Post-Market Registry […]
—ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch— —Clinical Programs Progressing on Track; Company Expects to Complete Enrollment in Phase 3 ASPEN Trial of Brensocatib in First Quarter of 2023 and […]
~ 3Q22 results in line with October 5, 2022 preliminary view ~ ~ Growth strategy fundamentals remain strong ~ PLANO, Texas, Oct. 27, 2022 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource manufacturer, today announced results for the three months ended September 30, 2022. Third Quarter 2022 Highlights (compared […]
— U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway — — Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – — Obtained Positive Scientific Assessment for Reimbursement in Italy and the Netherlands & Achieved Positive National Reimbursement in Finland […]
Q3 2022 reported revenue of $287.2 million, up 7.5% compared to Q3 2021 Q3 2022 constant currency revenue, organic* up 10.5% compared to Q3 2021 Q3 2022 GAAP operating margin of 6.5%, compared to 6.0% in Q3 2021 Q3 2022 non-GAAP operating margin* of 16.1%, compared to 14.8% in Q3 […]
Significant clinical progress in the treatment of stroke with glenzocimab: Positive results from the ACTIMIS phase 1b/2a study Patent granted to protect glenzocimab in thrombotic diseases in Europe until 2036 Obtained “PRIME” status from the European Medicines Agency More than 150 patients enrolled to date in the ACTISAVE Phase 2/3 […]
Third-Quarter Results Reflect Sustained Strong Business Momentum Across Key Growth Drivers as Well as Investment and Progress in the Pipeline Third-Quarter 2022 Worldwide Sales Were $15.0 Billion, an Increase of 14% From Third-Quarter 2021; LAGEVRIO Sales Were $436 Million; Growth Excluding LAGEVRIO Was 10%; Growth Excluding LAGEVRIO and the Impact […]
Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis1 Third-quarter U.S. GAAP earnings (loss) per share (EPS) were ($5.83); Adjusted EPS totaled $0.82 Third-quarter results reflect impairment charges of $3.1 billion related to Baxter’s December […]
− Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO® – − Strong First Full Quarter of AMVUTTRA in U.S.: Achieving $25 Million in Net Product Revenues and Driving 30% U.S. Total TTR Growth Compared with Q2 2022 – − Reported Positive Results […]
